← All trials
NCT07202546
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2025
- Primary completion
- Jun 11, 2027
- Completion date
- Mar 19, 2029
- First posted
- Oct 2, 2025
- Last posted
- Oct 2, 2025
- Enrollment
- 550
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ViiV HealthcareLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.